|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
EP0557459B1
(en)
|
1990-11-13 |
1997-10-22 |
Immunex Corporation |
Bifunctional selectable fusion genes
|
|
WO1994028143A1
(en)
|
1993-05-21 |
1994-12-08 |
Targeted Genetics Corporation |
Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
|
|
US5814618A
(en)
|
1993-06-14 |
1998-09-29 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
|
US5464758A
(en)
|
1993-06-14 |
1995-11-07 |
Gossen; Manfred |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
|
EP1210428B1
(en)
|
1999-08-23 |
2015-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
JP2004501624A
(ja)
|
2000-06-28 |
2004-01-22 |
ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー |
Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
|
|
FR2814642B1
(fr)
|
2000-10-03 |
2005-07-01 |
Ass Pour Le Dev De La Rech En |
Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
|
|
KR20030066657A
(ko)
|
2000-11-15 |
2003-08-09 |
오노 야꾸힝 고교 가부시키가이샤 |
Ｐｄ-1 결손 마우스 및 그 용도
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
EP2388590A1
(en)
|
2001-04-02 |
2011-11-23 |
Dana Farber Cancer Institute |
PD-1, a receptor for B7-4, and uses thereof
|
|
US20040241745A1
(en)
|
2001-07-31 |
2004-12-02 |
Tasuku Honjo |
Substance specific to pd-1
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
EP1591527B1
(en)
|
2003-01-23 |
2015-08-26 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human pd-1
|
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
|
EP3130350A1
(en)
|
2005-06-08 |
2017-02-15 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
|
|
CA2611519A1
(en)
|
2005-06-17 |
2006-12-28 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
|
JP5093097B2
(ja)
|
2006-03-03 |
2012-12-05 |
小野薬品工業株式会社 |
細胞表面機能分子の細胞外領域多量体
|
|
CN101611054B
(zh)
*
|
2006-10-02 |
2013-12-25 |
Ac免疫有限公司 |
针对淀粉状蛋白β的人源化抗体
|
|
NZ720288A
(en)
|
2006-12-27 |
2020-02-28 |
Harvard College |
Compositions and methods for the treatment of infections and tumors
|
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
|
JP2010520748A
(ja)
|
2007-02-20 |
2010-06-17 |
アナプティスバイオ インコーポレイティッド |
体細胞超変異系
|
|
MY149129A
(en)
|
2007-03-20 |
2013-07-15 |
Lilly Co Eli |
Anti-sclerostin antibodies
|
|
EP3176264B1
(en)
|
2007-05-30 |
2018-09-26 |
Postech Academy-Industry- Foundation |
Immunoglobulin fusion proteins
|
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
US20120269806A1
(en)
|
2007-08-21 |
2012-10-25 |
The General Hospital Corporation |
Methods of inducing tolerance
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
RU2542967C2
(ru)
|
2007-10-05 |
2015-02-27 |
Дженентек, Инк. |
Применение антитела против амилоида бета при глазных заболеваниях
|
|
NZ586675A
(en)
|
2008-01-08 |
2012-04-27 |
Merck Sharp & Dohme |
Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
EP2307050A4
(en)
|
2008-07-04 |
2012-07-25 |
Ono Pharmaceutical Co |
USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP2927240A1
(en)
|
2008-08-25 |
2015-10-07 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
|
EP2342228B1
(en)
|
2008-09-12 |
2017-09-06 |
Oxford University Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
EP2342229A1
(en)
|
2008-09-12 |
2011-07-13 |
ISIS Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
ES2592216T3
(es)
|
2008-09-26 |
2016-11-28 |
Dana-Farber Cancer Institute, Inc. |
Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
CN102282265B
(zh)
|
2008-11-28 |
2020-07-24 |
埃默里大学 |
用于治疗传染病和肿瘤的方法
|
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
|
WO2011056772A1
(en)
|
2009-11-04 |
2011-05-12 |
Schering Corporation |
Engineered anti-tslp antibody
|
|
EP2519544A1
(en)
|
2009-12-29 |
2012-11-07 |
Emergent Product Development Seattle, LLC |
Polypeptide heterodimers and uses thereof
|
|
WO2011100841A1
(en)
|
2010-02-16 |
2011-08-25 |
Valorisation-Recherche, Limited Partnership |
Pd-1 modulation and uses thereof for modulating hiv replication
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
|
EP2547365A1
(en)
|
2010-03-17 |
2013-01-23 |
Abbott Research B.V. |
Anti-nerve growth factor (ngf) antibody compositions
|
|
CA2793309A1
(en)
|
2010-03-17 |
2011-09-22 |
Anaptysbio, Inc. |
Method of producing transcripts using cryptic splice sites
|
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
|
KR20130049196A
(ko)
|
2010-08-05 |
2013-05-13 |
에프. 호프만-라 로슈 아게 |
항-mhc 항체 항-바이러스성 사이토카인 융합 단백질
|
|
WO2012021851A2
(en)
|
2010-08-12 |
2012-02-16 |
Beth Israel Deaconess Medical Center |
Methods and compositions for diagnosing and treating lupus
|
|
WO2012031122A2
(en)
|
2010-09-03 |
2012-03-08 |
Immport Therapeutics, Inc. |
Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders
|
|
US9029315B2
(en)
|
2010-11-11 |
2015-05-12 |
The University Of Hong Kong |
Soluble PD-1 variants, fusion constructs, and uses thereof
|
|
CA2830349C
(en)
|
2011-03-17 |
2019-07-16 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
US9220776B2
(en)
|
2011-03-31 |
2015-12-29 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
|
|
CN102836441B
(zh)
|
2011-06-24 |
2019-06-11 |
台北荣民总医院 |
于感染性与恶性疾病的治疗中提升免疫反应的方法
|
|
AR087405A1
(es)
|
2011-08-01 |
2014-03-19 |
Genentech Inc |
Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
|
|
WO2013022091A1
(ja)
|
2011-08-11 |
2013-02-14 |
小野薬品工業株式会社 |
Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
|
|
CA2845536A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
WO2013177102A2
(en)
|
2012-05-21 |
2013-11-28 |
Felder Mitchell S |
Treatment of cancer by manipulating the immune system
|
|
WO2013174997A1
(en)
|
2012-05-25 |
2013-11-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies
|
|
EP2855528B1
(en)
|
2012-05-31 |
2019-06-19 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
|
HRP20210122T1
(hr)
|
2013-05-02 |
2021-04-16 |
Anaptysbio, Inc. |
Protutijela usmjerena protiv programirane smrti-1 (pd-1)
|
|
PE20160953A1
(es)
|
2013-12-12 |
2016-09-26 |
Shanghai hengrui pharmaceutical co ltd |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
EP3114144A1
(en)
|
2014-03-05 |
2017-01-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
WO2015145360A1
(en)
|
2014-03-24 |
2015-10-01 |
Glennie Martin J |
Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
|
|
DK3157956T3
(da)
|
2014-06-19 |
2020-04-27 |
Regeneron Pharma |
Ikke-humane dyr med et humaniseret gen med programmeret celledød 1
|
|
CA2957258C
(en)
|
2014-08-05 |
2023-11-07 |
MabQuest SA |
Immunological reagents
|
|
WO2016029073A2
(en)
*
|
2014-08-22 |
2016-02-25 |
Bristol-Myers Squibb Company |
Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
|
|
EA201790737A1
(ru)
|
2014-10-03 |
2017-08-31 |
Новартис Аг |
Комбинированная терапия
|
|
MX382902B
(es)
|
2014-10-31 |
2025-03-13 |
Oncomed Pharm Inc |
Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
|
|
MA41217A
(fr)
|
2014-12-19 |
2017-10-24 |
Advaxis Inc |
Polythérapies ayant des souches de listeria recombinées
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
CA2971734C
(en)
|
2014-12-22 |
2025-11-18 |
Enumeral Biomedical Holdings Inc |
Anti-pd-1 antibodies
|
|
CA2972757A1
(en)
|
2014-12-31 |
2016-07-07 |
Arthur M. Krieg |
Combination tumor immunotherapy
|
|
WO2016112870A1
(en)
|
2015-01-16 |
2016-07-21 |
Tse-Wen Chang |
Molecular constructs with targeting and effector elements
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
SG10201909173PA
(en)
|
2015-04-01 |
2019-11-28 |
Anaptysbio Inc |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
NZ735820A
(en)
*
|
2015-04-17 |
2025-02-28 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
|
JP2018515474A
(ja)
|
2015-04-28 |
2018-06-14 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
EP3478286B1
(en)
|
2016-06-29 |
2024-01-03 |
Tesaro, Inc. |
Methods of treating ovarian cancer
|
|
EP3666794A1
(en)
*
|
2016-11-01 |
2020-06-17 |
AnaptysBio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
EP3689419A1
(en)
|
2016-11-01 |
2020-08-05 |
AnaptysBio, Inc. |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
TW201825512A
(zh)
*
|
2016-11-29 |
2018-07-16 |
美商提薩羅有限公司 |
針對計劃性死亡-１（ｐｄ-１）之抗體
|
|
CN110382545A
(zh)
|
2017-01-09 |
2019-10-25 |
泰萨罗公司 |
用抗pd-1抗体治疗癌症的方法
|
|
CN110382000A
(zh)
|
2017-01-09 |
2019-10-25 |
泰萨罗公司 |
用抗tim-3抗体治疗癌症的方法
|
|
CA3076515A1
(en)
|
2017-09-30 |
2019-04-04 |
Tesaro, Inc. |
Combination therapies for treating cancer
|
|
TWI852940B
(zh)
|
2018-09-04 |
2024-08-21 |
美商泰沙羅公司 |
治療癌症之方法
|